A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

Similar documents
Highlighting in the WHO European Region: Summary. No. 21(February 2012)

Highlighting in the WHO European Region:

Highlighting in the WHO European Region: measles outbreaks rubella surveillance acute flaccid paralysis surveillance

A report on the epidemiology of selected vaccine-preventable diseases in the European Region

Alcohol-related harm in Europe and the WHO policy response

World Health Organization Regional Office for Europe Surveillance of measles and rubella Data as of 15 March 2006

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

European status report on alcohol and health Leadership, awareness and commitment

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON

EURO POLIO PAGE Data as of 04 October 2005 (Week 38)

Analysis of 3-dose oral/inactivated poliovirus vaccine (OPV3/IPV3) immunization coverage

Situation update in the European Region: overview of influenza surveillance data week 40/2009 to week 07/2010.

The cancer burden in the European Union and the European Region: the current situation and a way forward

Summary. Primary care data. Week 49/2014. Season

Monthly measles and rubella monitoring report

European Status report on Alcohol and Health

Q1 What age are you?

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SERBIA

Animal health situation of OIE Member Countries in Europe 1 st semester 2012 (and previous)

Measles and rubella monitoring January 2015

WHO EpiBrief. A report on the epidemiology of selected vaccine-preventable diseases in the European Region

Welcome to the new EURO Immunization Monitor

WHO Meeting on Strengthening measles and rubella laboratory network in the Russian Federation and Newly Independent States

Where we stand in EFORT

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

The State of Measles and Rubella in the WHO European Region

Noncommunicable diseases progress monitoring. Are we meeting the time-bound United Nations targets?

Reflecting on ten years of progress in the fight against AIDS, TB and malaria

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

SEVENTH MEETING OF THE EUROPEAN REGIONAL VERIFICATION COMMISSION FOR MEASLES AND RUBELLA ELIMINATION (RVC) June 2018 Paris, France

Smokefree Policies in Europe: Are we there yet?

Tenth meeting of the European Technical Advisory Group of Experts on Immunization: Outcomes and recommendations

EUVAC.NET A surveillance network for vaccine-preventable diseases

Engagement in language assessment / Regions of Europe

EUDY JUNIOR CAMP 2018 FIRST ANNOUNCEMENT

Overview of drug-induced deaths in Europe - What does the data tell us?

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

LEBANON. WCPT COUNTRY PROFILE December 2018

Inequality in injury risks

DENMARK. WCPT COUNTRY PROFILE December 2018

Report of the 27th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication

Report of the 26th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication

Monitoring noncommunicable disease commitments in Europe Theme in focus: progress monitor indicators

GERMANY. WCPT COUNTRY PROFILE December 2018

Third meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC) November 2014 Copenhagen, Denmark

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 25% 20% 15% 10%

Hepatitis C in the WHO European Region

Cardiovascular disease in Europe: epidemiological update 2016

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

Vaccinations pre- and posttransplant. Burkhard Tönshoff, MD, PhD University Children s Hospital Heidelberg, Germany

Development of Palliative Care services in different countries

Access to treatment and disease burden

Table 7.1 Summary information for lung cancer in Ireland,

Better Health for All in Latvia

Positioning health equity and the social determinants of health on the regional development agenda Investment for health and development in Slovenia

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

EUDY CHILDREN CAMP 2017 FIRST ANNONUCEMENT

Acknowledgements. Wild birds and the risk of a pandemic. Overview of the presentation

Eliminating measles and rubella and preventing congenital rubella infection

European monthly measles monitoring (EMMO)

Hepatitis A SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

REPORT OF THE 31ST MEETING OF THE EUROPEAN REGIONAL CERTIFICATION COMMISSION FOR POLIOMYELITIS ERADICATION (RCC)

SEASONAL INFLUENZA IN THE WHO EUROPEAN REGION, EARLY SEASON. Situational analysis

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

Prevention of Oral Cancer Special Interest Working Group

Real Life, Real PD Survey

European Association of Dental Public Health Prevention of Oral Cancer

Priorities for achieving Millennium Development Goals (MDGs) 4 and 5 in the European Region

11 Melanoma of the skin

Overall survival: 1 st line therapy

Fifth Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC)

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

Critical immunity thresholds for measles elimination

SURVEILLANCE REPORT. Measles and rubella surveillance

National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches

REVIEW OF THE ANALYSIS RELATED TO RABIES DIAGNOSIS AND FOLLOW-UP OF ORAL VACCINATION PERFORMED IN NRLS IN 2015

Key issues for HIV testing and

Table 9.1 Summary information for stomach cancer in Ireland,

Table 6.1 Summary information for colorectal cancer in Ireland,

Drug Prices Report Opioids Retail and wholesale prices * and purity levels,by drug, region and country or territory (prices expressed in US$ )

Cross Border Genetic Testing for Rare Diseases

State of Health In EU: Community Pharmacy Contribution

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

The challenge of obesity in the WHO European Region

The EHRA White Book 2009 The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

Seventh GF-TADs for Europe Steering Committee meeting (RSC7)

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

CALL FOR A EUROPEAN ACTION PLAN FOR MEDICAL IMAGING TO IMPROVE QUALITY OF CARE AND PATIENT SAFETY

European Collaboration on Dementia. Luxembourg, 13 December 2006

Transcription:

% of reported measles cases WHO EpiBrief A report on the epidemiology of selected vaccine-preventable diseases in the European Region No. /17 This issue of WHO EpiBrief provides an overview of selected epidemiological characteristics of measles and rubella in the WHO European Region based on monthly surveillance data. The surveillance data presented in this issue were reported by Member States and are incorporated in the centralized information system for infectious diseases (CISID). 1 Tabulated surveillance data by country for the first half of 17 (as of August 17) are annexed to this issue. The analyses of these data are performed on cases with disease onset dates during the first half of 17. Where these dates were unavailable, cases with the date of notification reported during this period were included. The numbers of cases in a specified time period may differ from reports produced by national or partner agencies if different dates are used. Percentages in this report were rounded to the nearest whole number. Measles in the WHO European Region January-June 17 Incidence notifications and laboratory data For the first half of 17, 93 measles cases were reported in countries of the WHO European Region among 5 (9%) countries that submitted measles data (including zero reporting) (Table 1 in annex). Three countries, namely Monaco, San Marino and Turkmenistan, did not submit reports. Of the total cases, 95% (n=75) were reported by 1 countries: Italy (n=3; 39%), Romania (1; %), Ukraine (93; 1%), Germany (79; %), Tajikistan (55; %), France (35; %), Belgium (97; 3%), Bulgaria (11; %), Spain (11; %) and the Czech Republic (131; 1%). The highest incidence per million population for the first half of 17 was in Romania (9) followed by Tajikistan () and Italy (1). Of the total cases, 5315 (57%) were laboratory confirmed and (%) were epidemiologically linked. The remaining 111 cases (19%) were classified as clinically compatible. During the first half of 17, 975 measles virus sequences were reported to the Measles Nucleotide Surveillance database (MeaNS) by reference laboratories of the WHO European Region (as of August 17). The genotypes identified in the Region comprised D (n=5), B3 (57), H1 () and D9 (1). Overall, the predominant measles virus genotypes reported for the first half of 17 included several B3 lineages reported by 19 countries. The dominant strain in 1 countries was Dublin.IRL/.1 (5% of reported B3 sequences). Several measles virus genotype D lineages were also reported by 1 countries mostly Osaka.JPN/9.15, (5% of D sequences). Genotype H1, which is usually found in Asia, was reported by five countries in the Region. Age distribution Of those with known age group (n=93), 13 (11%) were under one year of age, (%) were 1 years of age, 1 (%) were 5 9 years of age, 31 (13%) were 1 19 years of age and 3973 (%) were years and older (Fig. 1). Fig. shows the age distribution of reported measles cases in the top six countries reporting cases: Italy, Romania, Ukraine, Germany, Tajikistan and France by proportion and agespecific incidence. The classification of cases by age group for the two countries that reported 59% of cases Fig. 1. Age distribution of measles cases by proportion in the WHO European Region, January June 17 (n=93) 3% % 1% % 11% % % N.B. Discarded cases are not included. 7% % 1% % *WHO EpiData no. /17 is available separately at www.euro.who.int/ data/assets/pdf_file/11/337/17 Epi_Data_EN_July1_June17.pdf?ua=1 No. /17 Page 1

% of reported measles cases Incidence of reported measles cases per 1, inhabitants % of reported measles cases Incidence of reported measles cases per 1, inhabitants % of reported measles cases Incidence of reported measles cases per 1, inhabitants % of reported measles cases Incidence of reported measles cases per 1, inhabitants WHO EpiBrief EPI-BRIEF Fig.. Age distribution of measles cases by proportion (left) and incidence per 1 inhabitants (right) in the four countries that reported 77% of cases with data on age in the WHO European Region, January June 17 (n=73) 5% % Italy Romania (n=3) ITALY (n=3) 3% 5.5 Italy (n=3) ITALY 3% % 1% % % 5% % 5% 5% 3 1...9. 15. 3.7 % 5% % % Romania 37% 1% (n=1) 7% 5% 7% 7% 37% 5 9. Romania (n=1) 3% 15 % % 1% 1 97.3 1% % 5% % 3% % 1% % 5% % 3% % 1% % 7% 5% 7% 7% % Ukraine UKRAINE (n=93) % 9% 1% 7% 1% % 13% Germany GERMANY (n=79) 1% 11% 1% % 1% 19% 5 1 1 1 1 1 1 31....3 1. Ukraine (n=93) 1. 1.9 7.1.7 3.3 1.7. 15.5 Germany (n=79).... 1..3 Page No. /17

cases Number of reported measles cases Number of reported measles cases WHO EpiBrief (Italy and Romania) is presented in Fig 3. Vaccination status Vaccination status was known in 7 cases (%), of which 51 cases (3%) were unvaccinated and 99 cases (17%) were reportedly vaccinated with at least one measles-containing vaccine dose. Of the 51 unvaccinated cases: cases (1%) were <1 year old, 19 cases (3%) were 1 years old, 79 cases (1%) were 5 9 years old, 751 cases (11%) were 1 19 years old and 79 cases (%) were years old. Measles-related deaths During this period 13 measles-related deaths were reported in six countries: six in Romania, two in Italy and one each in Bulgaria, Germany, Portugal, Spain and Switzerland. With the exception of two fatal cases, none had received a measles vaccine. The fatal cases in Romania and Bulgaria were infants and young children (<3 years old), those in Italy were older children and 9 years old, and those in Germany, Portugal, Spain and Switzerland were 37, 17, 7 and 5 years old, respectively. Hospitalization Data on hospitalization status was available for 7% (n=39) of all reported measles cases. Of these, 3 were hospitalized, amounting to 7% of all cases with known hospitalization status. Of all the hospitalized cases, most were reported in Romania (n=15; 5%) and Tajikistan (9; 1%). Imported cases Importation status was known for 7% (n=731) of cases. Of these, 19 were reported as imported cases, amounting to.7% of cases with a known importation 1, Italy (n=3) status. Of all the imported cases, most (1%; n=13) were reported by Germany (), Italy (31), United Kingdom (n=5), France (3) and Spain (17). Rubella in the WHO European Region January-June 17 Incidence notifications and laboratory data For the first half of 17, 3 rubella cases were reported in 1 countries of the WHO European Region among 5 (5%) countries submitting rubella data (including zero reporting) (Table in annex). Most cases were reported by Poland (n=53; 5%), followed by Italy (; %), Germany (; 11%) and Austria (; 7%). For the first half of 17, Poland also had the highest incidence per million population (.) however, no cases were laboratory confirmed. Of the total, 71 (1%) cases were laboratory confirmed, most of which were reported by Italy (n=), Austria (3) and Germany (1). No rubella virus sequences were reported to the Rubella Nucleotide Surveillance database (RubeNS). 3 Age distribution The age group was known in all cases: 3 cases (1%) were <1 years old, 1 cases (5%) were 1 9 years old, cases (%) were 1 19 years old and 11 cases (%) were years old (Fig. ). The classification of cases by age group for the four countries that reported 95% of cases in the Region is presented in Fig 5. Vaccination status Vaccination status was known in 33 of cases (%). Of the 17 (51%) unvaccinated cases, 3 cases (1%) Fig. 3. Classification of measles cases by age group in Italy and Romania that together reported 59% of cases with data on age in the WHO European Region, January June 17 (n=55) 1, Romania (n=1) 1, 1, Clinically compatible Epidemiologically linked Laboratory confirmed No. /17 Page 3

cases Number of reported rubella cases Number of reported rubella cases Number of reported rubella cases Number of reported rubella cases % of reported rubella cases WHO EpiBrief Fig.. Age distribution of rubella cases in the WHO European Region, January June 17 (n=3) 3% % 1% % 1% % 7% N.B. Discarded cases are not included. were <1 year old, 3 cases (1%) were 1 years old, cases (15%) were 5 9 years old, 1 cases (%) were 1 1 years old and cases (3%) were 15 years old. The remaining 1 cases (9%) were reportedly vaccinated with at least one rubella-containing 9% % 9% 17% vaccine dose. Of these, 1 cases were reported by Poland. Imported cases Importation status was known in % (n=95) of rubella cases. Of these, 3 cases were reported as imported, amounting to 3.% of cases with a known importation status. The imported cases were reported from Austria (n=1), Czech Republic (1) and the United Kingdom (1). Comments Measles and rubella in the WHO European Region With 935, the total number of measles cases reported in the European Region for the first half of 17 exceeded the number reported for the entire year of 1 (n=519). This is predominantly due to continued measles transmission in Italy and Romania, but also significant increases in reported cases in a number of countries including Belgium, Bulgaria, Czech Republic, France, Germany, Spain, Tajikistan and Ukraine. Fig. 5. Classification of rubella cases by age group in the four countries that reported 95% of cases with data on age in the WHO European Region, January June 17 (n=37) 1 1 1 Poland (n=53) Germany (n=) 1 1 1 1 Italy (n=) Austria (n=) Clinically compatible Epidemiologically linked Laboratory confirmed Page No. /17

WHO EpiBrief The total for 17 is expected to become much higher still, due to delayed reporting of cases and continued outbreaks. Countries with large outbreaks often face challenges in timely collection of subnational surveillance data and thus, the submission of consolidated national data to international agencies is delayed. In addition, outbreaks in Italy and Romania are continuing. Updates on the number of cases in Italy and Romania are available online on their respective health authorities website.,5 The number of reported rubella cases in the Region for the first half of 17 was 5% lower than that reported for the same period in 1 (n=913). This is primarily due to a 7% decline in reported rubella cases in Poland, from 7 cases for the first half of 1 to 53 cases for the same period in 17. All of the reported cases in Poland in 17 were classified as clinically compatible. On the other hand, un- and/or under-vaccinated cases among children 1 9 years of age (3%) reflect sub-optimal routine immunization coverage rates in recent years. All eligible children in this age group should have received at least one vaccine dose according to national immunization programme schedules. Immunization coverage of at least 95% with two doses of a measles-containing vaccine needs to be reached and maintained at national level and in all districts through the routine immunization programme. Every country needs to actively identify reasons for the presence of un- and/or under-vaccinated individuals in the community and devise tailored strategies to address the identified challenges in their immunization programmes. Attaining and maintaining high population immunity is crucial to stop ongoing measles and rubella transmission and prevent outbreaks in the Region. At a regional level, the proportion of measles cases was highest in adults years and older (%) demonstrating immunity gaps in this population group in some countries. More efforts are needed to identify susceptible individuals and systematically address their vaccination needs. References 1. World Health Organization. Centralized Information system for infectious diseases (CISID). Copenhagen. Regional Office for Europe. http://data.euro.who.int/cisid/. Measles Nucleotide Surveillance database (MeaNS). www.who-measles.org 3. Rubella Nucleotide Surveillance database (RubeNS). www.who-rubella.org. Ministry of Health. National Institute of Health. Morbillo in Italia. Weekly bulletin. http://www.epicentro.iss.it/problemi/ morbillo/infografica17.asp 5. National Institute of Public Health, Romania. Rujeola, weekly updates. (in Romanian). http://cnscbt.ro/index.php/ informari-saptamanale/rujeola-1 Date of publication: September 17 Suggested citation: WHO EpiBrief, 17, :1 World Health Organization, 17 No. /17 Page 5

Lab confirmed Epi-Link Clinically compatible Discarded Measles Imported cases Completeness Timeliness Month & year of last report Laboratory investigation rate Rate of discarded cases Origin of infection Timeliness of investigation Annex Table 1. Measles cases: classification, reporting and surveillance performance, January June 17 (as of 1 August 17) 1 (as of 1 August 17) 17 Classification Reporting Surveillance Indicators Country Total Population in 17 1 Incidence Rate (per 1 million population) Total measles cases 3 Annualized Incidence Rate (per 1 million population) Total measles cases 3 Albania 911.. 1% 3% Jun-17 -. - - Andorra 77.. 3% 5% May-17 -. - - Armenia 3 31 7.7. 3 3% 3% May-17 1% 1. 1% 97% Austria 59 1..1 7 7 1 1 5 1% 1% Jun-17 9%.5 93% 5% Azerbaijan 9 973 97..1 5 1% 1% Jun-17 9%.5 % 57% Belarus 9 5 535 1. 9. 1 1 15 1 1% 1% Jun-17 1% 1.53 1% 1% Belgium 11 3 3. 5 13. 97 97 1% 7% Jun-17 %. Bosnia and Herzegovina 3 79 759 11.9 5.1 1 1 3% 7% Jun-17 %. Bulgaria 7 5 59.1 1 11. 11 5 5 11 3 3% 3% Jun-17 97%. 3% 1% Croatia 9 15.. 7 7 1 1% 3% Jun-17 1%. 75% Cyprus 1 17 575.. 3 3 1% 1% Jun-17 1%. 1% Czech Republic 1 555 13. 7.1 131 3 1 1% 1% Jun-17 1%.1 99% % Denmark 5 711 37. 3. 1 1 1 1% 1% Jun-17 1%. 1% Estonia 1 35 755.. 1 1 5 1 1% 1% Jun-17 1% 3.3 % 1% Finland 5 51 7.5 5. 1 1 1 1% 1% Jun-17 1%. 1% France 93 71 1. 79.5 35 9 5 71 3 1% 1% Jun-17 91%. 9% % Georgia 3 97 53 3.5 1. 3 3 1% 3% Jun-17 5%. 1% 1% Germany 3 3. 3.7 79 51 3 1% 1% Jun-17 9%. 7% Greece 1 9 931.. 3 1% 1% Jun-17 1%. 75% Hungary 9 77 95..7 15 15 17 1 1% 5% Jun-17 1%.17 3% 97% Iceland 33 33. 1 1.5 1 3% 3% Jun-17 1%. 5% 1% Ireland 79 153. 3.7 7 1 1% 1% Jun-17 7%. 57% 57% Israel 33 1. 1. 5% 33% May-17 %. Italy 59 797 97 13.7 1 3.3 3 797 37 7 31 3% 3% Jun-17 %. % Kazakhstan 1 7 5.9 1.1 1 1 3% 7% Jun-17 %. Kyrgyzstan 95..1 1 1 9 1% 3% Jun-17 99% 1.57 1% Latvia 1 9 55.. 1% 1% Jun-17 -. - - Lithuania 3 5 7.. 1 1 1 1% 3% Jun-17 1%. 1% Luxembourg 5 13..9 3 3 1% 1% Jun-17 1%. 7% 1% Malta 51.. 1% 1% Jun-17 -. - - Monaco 3 1 - - - - - - - - - - - No Report - - - - Montenegro 5.. 1 1% 7% Jun-17 1%.1 1% 1% Netherlands 17 3 5.1.1 5 1 1 1% 1% Jun-17 1%.1 1% Norway 5 33.. 1% 1% Jun-17 -. - - Poland 3 53 573. 13. 1 17 1 3 1% 1% Jun-17 5%. 15% 1% Portugal 1 797. 1. 3 13 1% 3% Jun-17 7% 1.7 1% 7% Republic of Moldova 5.. 1% 7% Jun-17 -. - - Romania 19 37 513. 3 7.7 1 5 115 3 7 1% 1% Jun-17 1%. 3% 1% Russian Federation 13 375 1.1 17.3 79 77 1 1 5 7 1% 7% Jun-17 1%.7 11% 7% San Marino 3 1 - - - - - - - - - - - No Report - - - - Serbia 77 9 1. 1. 7 7 1% 3% Jun-17 %. Slovakia 5 3 157.. 1% 1% Jun-17 7%.7 1% 7% Slovenia 71 5. 1 1. 1 1% 1% Jun-17 1%. 1% 1% Spain 7 1. 3 1.3 11 135 95 17 1% 3% Jun-17 9%.1 % 7% Sweden 9 9. 3.9 9 1% 1% Jun-17 1%.9 1% Switzerland 5 3.3 3. 7 5 3 5 3 1% 1% Jun-17 9%. 51% 1% Tajikistan 5 115 5.9 5 5. 55 3 51 3% 3% May-17 1% 1.3 7% 1% The former Yugoslav Republic of Macedonia 3 3.. 1% 7% Jun-17 -. - - Turkey 17 5.1 9.1 19 1 1 1% % Jun-17 93%. Turkmenistan 5 5 5 - - - - - - - - - - - No Report - - - - Ukraine 5 55. 9 1. 93 9 5 1% 1% Jun-17 %. United Kingdom 5 511 9.1 571.5 9 9 5 1% 1% Jun-17 1%. % 1% Uzbekistan 3 9 91. 1. 3 1% 33% Jun-17 1%. 1% Total/Averages 91 91 19 5.3 519. 93 5315 111 9 5 9.9% 79.%.%.5.5% 33.% Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe or via ECDC/TESSy. 1 Source: " World Population Prospects: The 15 Revision", New York, United Nations. Incidence not meeting the target (<1) and countries not reporting monthly measles data are highlighted in red. The imported measles cases are excluded from the numerator while calculating the incidence rate. 3 All confirmed measles cases regardless of origin. Unless specified as laboratory confirmed or epi-linked, cases are classified as clinically compatible. Member States submitting aggregate data: Bosnia and Herzegovina, Kazakhstan, Republic of Moldova, San Marino, Serbia, the former Yugoslav Republic of Macedonia, Turkmenistan, Ukraine. Page No. /17

Lab confirmed Epi-Link Clinically compatible Discarded Rubella Imported cases Completeness Timeliness Month of last report Laboratory investigation rate Rate of discarded cases Origin of infection Timeliness of investigation WHO EpiBrief Table. Rubella cases: classification, reporting and surveillance performance, January June 17 (as of 1 August 17) 1 (as of 1 August 17) 17 Classification Reporting Surveillance Indicators Country Total Population in 17 1 Incidence Rate (per 1 million population) Total rubella cases 3 Annualized Incidence Rate (per 1 million population) Total rubella cases 3 Albania 911.. 1% 3% Jun-17 -. - - Andorra 77.. 3% 5% May-17 -. - - Armenia 3 31 7.. 3% 3% May-17 1%. 1% 1% Austria 59.3 3 1.5 3 1 1 1% 1% Jun-17 1%. 1% % Azerbaijan 9 973 97..1 1 1 1% 1% Jun-17 97%. % 59% Belarus 9 5 535 - -. 15 1% 1% Jun-17 % 1.53 % % Belgium 5 11 3 3 - - - - - - - - - - - See footnote - - - - Bosnia and Herzegovina 3 79 759.. 7% 5% Jun-17 -. - - Bulgaria 7 5 59. 3. 1% 1% Jun-17 -. - - Croatia 9 15.. 1% 5% Jun-17 -. - - Cyprus 1 17 575.. 1% 1% Jun-17 -. - - Czech Republic 1 555 13.. 1 1% 1% Jun-17 1%. 5% % Denmark 5 5 711 37 - - - - - - - - - - - See footnote - - - - Estonia 1 35 755.. 1 1% 1% Jun-17 95% 1.1 % 1% Finland 5 51 7.. 1% 1% Jun-17 -. - - France 5 93 71 - - - - - - - - - - - See footnote - - - - Georgia 3 97 53 3.. 3 1 3 1% 3% Jun-17 1%.91 1% 97% Germany 3 1. 9.3 1 3 9 1% 1% Jun-17 %. 3% % Greece 1 9 931.. 1% 1% Jun-17 -. - - Hungary 9 77 95.. 7% 33% Jun-17 -. - - Iceland 33 33.. 1% 3% Jun-17 -. - - Ireland 79 153. 1.1 1 1 1% 1% Jun-17 %. % % Israel 33.1 1. 5% 33% May-17 -. - - Italy 59 797 97.5 31. 1 3 1% 3% Jun-17 %. 7% % Kazakhstan 1 7.. 3% 7% Jun-17 -. - - Kyrgyzstan 95.3. 1% 3% Jun-17 1%. 1% % Latvia 1 9 55.. 1% 1% Jun-17 -. - - Lithuania 3 5.. 1% 3% Jun-17 -. - - Luxembourg 5 13.. 1% 1% Jun-17 -. - - Malta 51.. 1% 1% Jun-17 -. - - Monaco 3 1 - - - - - - - - - - - No Report - - - - Montenegro 5.. 7% 33% Apr-17 -. - - Netherlands 17 3 5.. 1% 1% Jun-17 -. - - Norway 5 33.. 1% 1% Jun-17 -. - - Poland 3 53 573 9.7 11 3.3 53 53 1% 1% Jun-17 %. % % Portugal 1 797.. 1 1 1% 7% Jun-17 7%. 1% 1% Republic of Moldova 5.. 1% 7% Jun-17 -. - - Romania 19 37 513.7 13.1 3 1 7% 5% Jun-17 75%. 1% 1% Russian Federation 13 375. 37. 3 3 1% 7% Jun-17 1%. 1% % San Marino 3 1 - - - - - - - - - - - No Report - - - - Serbia 77 9 - - - - - - - - - - - No Report - - - - Slovakia 5 3 157..1 1 1 1 1% 1% Jun-17 5%. 5% 5% Slovenia 71 5.. 1% 1% Jun-17 -. - - Spain 7 1.. 11 1% 1% Jun-17 1%. 1% 1% Sweden 9 9.. 1% 1% Jun-17 -. - - Switzerland 5 3.. 11 1% 1% Jun-17 %.13 % 7% Tajikistan 5 115.1 1.1 1 1 7 7% 7% May-17 1%. 1% 1% The former Yugoslav Republic of Macedonia 3 3.. 1% 7% Jun-17 -. - - Turkey 17 5 - - - - - - - - - - - No Report - - - - Turkmenistan 5 5 5 - - - - - - - - - - - No Report - - - - Ukraine 5 55 - - - - - - - - - - - No Report - - - - United Kingdom 5 511 9.. 1 1 1 1% 1% Jun-17 1%. 1% 1% Uzbekistan 3 9 91.. 1 1 1% 33% Jun-17 1%. 1% % Total/Averages 91 91 19 1.5 13. 3 71 39 91 3 79.% 9.5% 3.1%.3 7.5% 1.9% Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe or via ECDC/TESSy. 1 Source: World Population Prospects: The 15 Revision", New York, United Nations. Incidence not meeting the target (<1) and countries not reporting monthly rubella data are highlighted in red. The imported rubella cases are excluded from the numerator while calculating the incidence rate. 3 All confirmed rubella cases regardless of origin. Unless specified as laboratory confirmed or epi-linked, cases are classified as clinically compatible. 5 Belgium, Denmark, and France do not have comprehensive rubella surveillance systems. Member States submitting aggregate data: Bosnia and Herzegovina, Kazakhstan, Republic of Moldova, San Marino, Serbia, the former Yugoslav Republic of Macedonia, Turkmenistan, Ukraine. No. /17 Page 7

Number of sequences reported Number of sequences reported Fig 1. Distribution of named strains of D measles genotype in the WHO European Region by week of sample collection, January June 17 (data as of August 17) 35 D - Not named D - MVs/Osaka.JPN/9.15/ D - MVs/Victoria.AUS/.11/ D - MVs/Frankfurt Main.DEU/17.11/ D - MVs/Cambridge.GBR/5.1/ D - MVi/Hulu Langat.MYS/.11/ 3 5 15 1 5 1 3 5 7 9 1 11 13 1 15 1 17 1 19 1 5 17 Week of sample collection Fig. Distribution of named strains of B3 measles genotype in the WHO European Region by week of sample collection, January June 17 (data as of August 17) 35 B3 - Not named B3 - MVs/Kabul.AFG/.1/3 B3 - MVs/Niger.NGA/.13/ B3 - MVs/Dublin.IRL/.1/ B3 - MVs/Kansas.USA/1./ B3 - MVi/Harare.ZWE/3.9/ 3 5 15 1 5 1 3 5 7 9 1 11 13 1 15 1 17 1 19 1 3 5 17 Week of sample collection Page No. /17